1. Home
  2. CTS vs TSHA Comparison

CTS vs TSHA Comparison

Compare CTS & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CTS Corporation

CTS

CTS Corporation

HOLD

Current Price

$44.31

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

HOLD

Current Price

$5.87

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTS
TSHA
Founded
1896
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.2B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
CTS
TSHA
Price
$44.31
$5.87
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$10.22
AVG Volume (30 Days)
191.3K
3.4M
Earning Date
02-03-2026
11-04-2025
Dividend Yield
0.36%
N/A
EPS Growth
3.07
N/A
EPS
1.98
N/A
Revenue
$531,522,000.00
$6,310,000.00
Revenue This Year
$5.73
N/A
Revenue Next Year
$4.00
N/A
P/E Ratio
$22.47
N/A
Revenue Growth
3.61
N/A
52 Week Low
$34.02
$1.05
52 Week High
$57.49
$5.95

Technical Indicators

Market Signals
Indicator
CTS
TSHA
Relative Strength Index (RSI) 56.37 68.29
Support Level $42.68 $5.22
Resistance Level $45.71 $5.54
Average True Range (ATR) 1.21 0.32
MACD 0.09 0.14
Stochastic Oscillator 65.27 96.09

Price Performance

Historical Comparison
CTS
TSHA

About CTS CTS Corporation

CTS Corp operates in the electronics industry. The company is a manufacturer of Sensors, Electronic components, and Actuators. It designs, manufactures, and sells a broad line of sensors, electronic components, and actuators mainly to original equipment manufacturers (OEM) for the aerospace and defense, industrial, information technology, medical, telecommunications, and transportation markets. Geographically, it derives a majority of its revenue from the United States and also has a presence in China; Singapore; the Czech Republic; Taiwan, Denmark, and other countries.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Share on Social Networks: